

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-42. (Canceled)

43. (Currently amended) A pharmaceutical composition comprising:

(i) an oligonucleotide consisting of between 10-30 nucleotide units, which contains three adjacently located nucleotide sequences, A, B and C, in the following order (5' to 3'):

A-B-C or C-B-A,

in which

A consists of between 2 and 10 nucleotide units, wherein between 1 and 5 of the nucleotide units in A are locked nucleotide units;

B consists of between 1 and 10 nucleotide units, wherein B comprises nucleotide units selected from the group consisting of 2'-deoxy-erythro-pentofuranosyl, ribo-pentofuranosyl and alpha-L-oxy LNA nucleotide units, wherein B comprises at least one alpha-L-oxy LNA nucleotide unit;

C consists of between 2 and 10 nucleotides units wherein between 1 and 5 of the nucleotide units in C ||A|| are locked nucleotide units; and

(ii) a pharmaceutical carrier.

44. (Previously presented) The pharmaceutical composition according to claim 43, in which B represents a sequence of nucleotide units that makes the oligonucleotide able to recruit RNase H when the oligonucleotide is hybridized to a target RNA molecule.

45. (Currently amended) The pharmaceutical composition according to claim 44, in which B consists of ~~nucleotide units selected from the group consisting of~~ 2'-deoxy-erythro-pentofuranosyl nucleotide units and alpha-L-oxy LNA nucleotide units.

46. (Previously presented) The pharmaceutical composition according to claim 45, wherein the locked nucleotide units in A and C are selected from the group consisting of oxy-LNA, thio-LNA and amino-LNA nucleotide units, wherein the LNA nucleotide units are in either the alpha or beta configuration.

47. (Previously presented) The pharmaceutical composition according to claim 45, wherein the locked nucleotide units in A and C are beta-D-oxy-LNA nucleotide units.

48 - 53. (Canceled)

54. (Previously presented) The pharmaceutical composition according to claim 45, wherein A consists of 1, 2, 3, 4 or 5 LNA nucleotide units.

55. (Previously presented) The pharmaceutical composition according to claim 45, wherein C consists of 2, 3, 4 or 5 LNA nucleotide units.

56. (Previously presented) The pharmaceutical composition according to claim 54, wherein C consists of 2, 3, 4 or 5 LNA nucleotide units.

57. (Previously presented) The pharmaceutical composition according to claim 45, wherein the oligonucleotide consists of 10-20 nucleotide units.

58. (Previously presented) The pharmaceutical composition according to claim 45, wherein the oligonucleotide consists of 12-18 nucleotide units.

59. (Previously presented) The pharmaceutical composition according to claim 45, wherein the oligonucleotide consists of 13, 14, 15, 16 or 17 nucleotide units.

60. (Previously presented) The pharmaceutical composition according to claim 45, wherein the oligonucleotide consists of 16 nucleotide units.

61. (Canceled)

62. (Previously presented) The pharmaceutical composition according to claim 45, wherein B consists of 5, 6, 7 or 8 nucleotide units.

63 – 64. (Canceled)

65. (Previously presented) The pharmaceutical composition according to claim 45, in which the linkages between the nucleotide units in the oligonucleotide comprise at least one linkage which is not a -O-P(O)<sub>2</sub>-O- linkage

66. (Currently amended) The pharmaceutical composition according to claim 45, in which the linkages between the nucleotide units in B in the oligonucleotide comprises at least one phosphothioate linkage which is not a -O-P(O)<sub>2</sub>-O- linkage.

67. (Previously presented) The pharmaceutical composition according claim 45, wherein the linkages between the nucleotide units are phosphorothioate internucleoside linkages.

68. (Previously presented) The pharmaceutical composition according to claim 45, which further comprises other antisense compounds, chemotherapeutic compounds, antiinflammatory compounds and/or antiviral compounds.